SynthesisHuman vaccines & immunotherapeutics2018

A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model.

Roland Kratzer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.